Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

heron therapeutics inc. - HRTX

HRTX

Close Chg Chg %
1.21 0.05 4.13%

Closed Market

1.26

+0.05 (4.13%)

Volume: 1.14M

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: heron therapeutics inc. - HRTX

HRTX Key Data

Open

$1.23

 Day Range

1.19 - 1.28

52 Week Range

1.00 - 2.68

 Market Cap

$242.04M

Shares Outstanding

183.36M

 Public Float

181.48M

Beta

1.25

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.08

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.48M

  

HRTX Performance

1 Week
 
 -4.55%
 
1 Month
 
 -9.35%
 
3 Months
 
 14.55%
 
1 Year
 
 -27.59%
 
5 Years
 
 -93.13%
 

HRTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About heron therapeutics inc. - HRTX

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

HRTX At a Glance

Heron Therapeutics, Inc.
100 Regency Forest Drive
Cary, North Carolina 27518
Phone 1-858-251-4400 Revenue 144.29M
Industry Biotechnology Net Income -13,580,000.00
Sector Health Technology 2024 Sales Growth 13.571%
Fiscal Year-end 12 / 2025 Employees 122
View SEC Filings

HRTX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.617
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -38.925
Enterprise Value to Sales 2.438
Total Debt to Enterprise Value 0.505

HRTX Efficiency

Revenue/Employee 1,182,663.934
Income Per Employee -111,311.475
Receivables Turnover 1.829
Total Asset Turnover 0.633

HRTX Liquidity

Current Ratio 2.285
Quick Ratio 1.704
Cash Ratio 0.648

HRTX Profitability

Gross Margin 73.214
Operating Margin -7.99
Pretax Margin -9.412
Net Margin -9.412
Return on Assets -5.961
Return on Equity N/A
Return on Total Capital -9.423
Return on Invested Capital -9.575

HRTX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 123.351
Total Debt to Total Assets 76.245
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 121.243

Snapshot

Average Recommendation BUY Average Target Price 4.50
Number of Ratings 4 Current Quarters Estimate -0.023
FY Report Date 12 / 2025 Current Year's Estimate N/A
Last Quarter’s Earnings -0.10 Median PE on CY Estimate N/A
Year Ago Earnings -0.10 Next Fiscal Year Estimate 0.122
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 N/A 4 3
Mean Estimate -0.02 N/A 0.00 0.12
High Estimates 0.00 N/A 0.05 0.15
Low Estimate -0.03 N/A -0.05 0.09
Coefficient of Variance -66.67 N/A N/A 24.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Heron Therapeutics Inc. - HRTX

Date Name Shares Transaction Value
Nov 5, 2025 William P. Forbes EVP, Chief Development Officer 166,203 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 5, 2025 William P. Forbes EVP, Chief Development Officer 152,027 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 5, 2025 Craig A. Collard Chief Executive Officer; Director 523,124 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 5, 2025 Craig A. Collard Chief Executive Officer; Director 452,253 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 5, 2025 Ira Duarte EVP, Chief Financial Officer 179,786 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 5, 2025 Ira Duarte EVP, Chief Financial Officer 152,027 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Rubric Capital Management LP 29,100,728 Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share 43,651,092.00
Aug 13, 2025 Rubric Capital Management LP N/A Open market or private purchase of non-derivative security 0.00
Aug 13, 2025 Velan Capital Investment Management LP Director 8,753,290 Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share 13,129,935.00

Heron Therapeutics Inc. in the News